Peptides with Soft-Aggregation Behavior Inhibit and Reverse Amyloid-β Fibrillization.

Area of Science:

• Biochemistry
• Neuroscience
• Drug Discovery

Background:

• Amyloid-β (Aβ) fibrillization is a key pathological hallmark of Alzheimer's disease (AD).
• Current therapeutic strategies face challenges in completely inhibiting or reversing Aβ fibrillization.
• Developing novel approaches to target Aβ aggregation is crucial for AD treatment.

Purpose of the Study:

• To investigate a novel anti-fibrillization mechanism mediated by short peptides exhibiting soft-aggregation behavior.
• To explore the potential of these peptides as a therapeutic strategy for Alzheimer's disease.
• To define and characterize soft-aggregation as a distinct mode of peptide self-assembly.

Main Methods:

• Systematic comparison of different peptides to correlate soft-aggregation with anti-fibrillization efficacy.
• Demonstration of Ana-5F peptide binding to hydrophobic fragments of Aβ.
• Inhibition and reversal of full-length Aβ fibrillization in vitro.
• Evaluation of Ana-5F efficacy in rat models of Alzheimer's disease.

Main Results:

• Short peptides demonstrated a novel soft-aggregation behavior, forming irregular nanoparticles driven by hydrophobic interactions.
• A direct correlation was confirmed between soft-aggregation and anti-fibrillization efficacy.
• The peptide Ana-5F effectively inhibited and reversed Aβ fibrillization, cleared mature Aβ fibrils in vivo, and ameliorated cognitive and behavioral deficits in rat models.

Conclusions:

• Soft-aggregation represents a novel peptide aggregation behavior distinct from classical ordered self-assembly.
• This mechanism provides a strategic approach for eliminating pathological Aβ fibrils.
• Peptides utilizing soft-aggregation, like Ana-5F, show significant therapeutic potential for Alzheimer's disease.